The recommendations for DBL Leucovorin Calcium rescue are based on a methotrexate dose of 12 to 15 g/m2 administered by intravenous infusion over four hours (see product information for methotrexate). DBL Leucovorin Calcium rescue at a dose of 15 mg (approximately 10 mg/m2) every six hours for ten doses starts 24 hours after the beginning of the methotrexate infusion. In the presence of gastrointestinal toxicity, nausea or vomiting, DBL Leucovorin Calcium should be administered parenterally. Serum creatinine and methotrexate levels should be determined at least once daily. DBL Leucovorin Calcium Injection administration, hydration and urinary alkalinisation (pH of 7.0 or greater) should be continued until the methotrexate level is below 5 x 10-8 M (0.05 micromolar). Foods, drinks and drugs that may increase urinary acidity should be avoided during the therapy. The DBL Leucovorin Calcium dose should be adjusted or folinic acid rescue extended based on the following guidelines shown in Table 1 ...

A comprehensive guide to side effects including common and rare side effects when taking Leucovorin Calcium (Leucovorin Calcium Tablets) includes uses, warnings, and drug interactions.

This phase II trial studies how well bevacizumab, fluorouracil, leucovorin calcium, and oxaliplatin before surgery works in treating patients with stage II-III rectal cancer. Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Drugs used in chemotherapy, such as fluorouracil, leucovorin calcium, and oxaliplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving bevacizumab together with fluorouracil, leucovorin calcium, and oxaliplatin may be an effective treatment for rectal cancer ...

PRIMARY OBJECTIVES:. I. To demonstrate an improvement in 3-year disease-free survival for high-risk stage II colon cancer patients randomly assigned to 5-FU (fluorouracil), leucovorin (leucovorin calcium), oxaliplatin versus 5-FU, leucovorin, oxaliplatin and bevacizumab.. SECONDARY OBJECTIVES:. I. To compare overall survival between the regimens. II. To further define the toxicity profiles of the regimens. III. To prospectively determine the impact of tumor biological characteristics on the survival of patients with stage II colon cancer.. IV. To assess the association between oxaliplatin exposure, allelic variants in candidate genes, and neurotoxicity. (Pharmacogenetic ancillary objective). OUTLINE: Patients with high-risk disease are randomized to 1 of 2 treatment arms (Arms A and B). Patients with low-risk disease are assigned to Arm C.. ARM A: Patients receive oxaliplatin intravenously (IV) over 2 hours and leucovorin calcium IV over 2 hours on day 1. Patients also receive fluorouracil IV ...

A form of folic acid used alone or with other drugs to treat certain types of colorectal cancer and anemia and to lessen the toxic effects of the anticancer drug methotrexate or other substances that block the action of folic acid. Leucovorin calcium is also being studied in the treatment of other conditions and types of cancer. It is a type of chemoprotective agent and a type of chemosensitizing agent. Leucovorin is the active ingredient of leucovorin calcium. Also called citrovorum factor and folinic acid ...

NDC Code 25021-816-67 is assigned to a package of 1 vial in 1 carton > 17.5 ml in 1 vial of Leucovorin Calcium, a human prescription drug labeled by Sagent Pharmaceuticals.

Hospira Leucovorin Calcium is a medicine available in a number of countries worldwide. A list of US medications equivalent to Hospira Leucovorin Calcium is available on the Drugs.com website.

TY - JOUR. T1 - A phase II study of continuous infusion 5‐fluorouracil and leucovorin with weekly cisplatin in metastatic colorectal carcinoma. AU - Grem, Jean L.. AU - McAtee, Nanette. AU - Balis, Frank. AU - Murphy, Robert. AU - Venzon, David. AU - Kramer, Barnett. AU - Goldspiel, Barry. AU - Begley, Martin. AU - Allegra, Carmen J.. PY - 1993/8/1. Y1 - 1993/8/1. N2 - Background. Prolonged infusional 5‐fluorouracil (5‐FU) and bolus 5‐FU modulated by leucovorin are associated with higher response rates than bolus 5‐FU alone. Cisplatin enhances 5‐FU cytotoxicity in some preclinical models. Methods. The authors tested the feasibility of combining concurrent infusional leucovorin (500 mg/m2/d) with protracted infusional 5‐FU (200 mg/m2/d) and weekly bolus cisplatin (20 mg/m2) in 22 patients with metastatic colorectal cancer. Results. Four partial responses (PR) were noticed among 21 evaluable patients (19%). The median time to treatment failure and median survival were 6 months and 11 ...

TY - JOUR. T1 - S-1 plus leucovorin and oxaliplatin versus S-1 plus cisplatin as first-line therapy in patients with advanced gastric cancer (SOLAR). T2 - a randomised, open-label, phase 3 trial. AU - Kang, Yoon Koo. AU - Chin, Keisho. AU - Chung, Hyun Cheol. AU - Kadowaki, Shigenori. AU - Oh, Sang Cheul. AU - Nakayama, Norisuke. AU - Lee, Keun Wook. AU - Hara, Hiroki. AU - Chung, Ik Joo. AU - Tsuda, Masahiro. AU - Park, Se Hoon. AU - Hosaka, Hisashi. AU - Hironaka, Shuichi. AU - Miyata, Yoshinori. AU - Ryu, Min Hee. AU - Baba, Hideo. AU - Hyodo, Ichinosuke. AU - Bang, Yung Jue. AU - Boku, Narikazu. PY - 2020/8. Y1 - 2020/8. N2 - Background: S-1 plus leucovorin and oxaliplatin showed promising efficacy for treatment of advanced gastric cancer in a randomised phase 2 study. We aimed to evaluate the efficacy and safety of oral TAS-118 (S-1 plus leucovorin) and oxaliplatin versus S-1 plus cisplatin in patients with advanced gastric cancer. Methods: We did a randomised, open-label, phase 3 trial in ...

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice. ...

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice. ...

Lederle Leucovorin: Leucovorin is a medication that acts the same way in the body as folic acid. Leucovorin is used to reduce the folic-acid-lowering side effects of methotrexate because it is not affected by methotrexate in the same way that folic acid is. Leucovorin is also used in combination with fluorouracil to treat cancer of the colon.

Sagent announced the launch of Leucovorin Calcium for Injection, a medication consistently appearing on the ASHSP and FDAs lists of drug shortages.

TY - JOUR. T1 - A multicenter, phase I/II trial of biweekly S-1, leucovorin, oxaliplatin and gemcitabine in metastatic pancreatic adenocarcinoma-TCOG T1211 study. AU - Chiang, Nai Jung. AU - Tsai, Kelvin K.. AU - Hsiao, Chin Fu. AU - Yang, Shih Hung. AU - Hsiao, Hui Hua. AU - Shen, Wen Chi. AU - Hsu, Chiun. AU - Lin, Yu Lin. AU - Chen, Jen Shi. AU - Shan, Yan Shen. AU - Chen, Li Tzong. PY - 2020/1. Y1 - 2020/1. N2 - Background: This phase I/II study evaluated the feasibility and efficacy of S-1, leucovorin, oxaliplatin and gemcitabine (SLOG), a triplet regimen, for treating patients with metastatic pancreatic ductal adenocarcinoma (PDAC). Methods: Patients with chemo-naive, metastatic PDAC were eligible to receive fixed-rate infusion (10 mg/m2/min) of gemcitabine of 800 mg/m2 followed by 85 mg/m oxaliplatin of 85 mg/m2 on day 1 plus oral S-1 and leucovorin (20 mg/m2) twice daily from days 1 to 7 in a 2-week cycle. The dose of S-1 would be escalated from 20, 30, 35 to 40 mg/m2 in a 3 + 3 designed ...

This is an open-label, nonrandomized phase I trial to determine the safety and maximum tolerated dose of irinotecan with a fixed dose of UFT plus oral leucovorin in patients with advanced or metastatic colorectal cancer.

OncoLink, the Webs first cancer resource,provides comprehensive information on coping with cancer, cancer treatments, cancer research advances, continuing medical education, cancer prevention, and clinical trials

What you need to know before starting 5FU + Leucovorin treatment for Colon Cancer, how its given and possible side effects. Get free tools to track your health.

FOLFOXIRI plus bevacizumab is used as a first-line therapy for patients with unresectable or metastatic colorectal cancer. However, there are no clear recommendations for second-line therapy after FOLFOXIRI plus bevacizumab combination. Here, we describe our planning for the EFFORT study to investigate whether FOLFIRI plus aflibercept has efficacy following FOLFOXIRI plus bevacizumab for mCRC. EFFORT is an open-label, multicenter, single arm phase II study to evaluate whether a FOLFIRI plus aflibercept has efficacy following FOLFOXIRI plus bevacizumab for mCRC. Patients with unresectable or metastatic colorectal cancer who received FOLFOXIRI plus bevacizumab as a first-line therapy will receive aflibercept and FOLFIRI (aflibercept 4 mg/kg, irinotecan 150 mg/m2 IV over 90 min, with levofolinate 200 mg/m2 IV over 2 h, followed by fluorouracil 400 mg/m2 bolus and fluorouracil 2400 mg/m2 continuous infusion over 46 h) every 2 weeks on day 1 of each cycle. The primary endpoint is progression-free survival

The U.S. Food and Drug Administration has approved irinotecan liposome injection (Onivyde), in combination with fluorouracil (5-FU) and leucovorin, to treat patients with metastatic pancreatic cancer who have been previously treated with gemcitabine-based chemotherapy.. The effectiveness of liposomal irinotecan was demonstrated in a three-arm, randomized, open-label study of 417 patients with metastatic pancreatic adenocarcinoma whose cancer had grown after receiving the chemotherapeutic drug gemcitabine or a gemcitabine-based therapy.1 The study was designed to determine whether patients receiving liposomal irinotecan plus 5-FU/leucovorin or liposomal irinotecan alone lived longer than those receiving 5-FU/leucovorin.. Patients treated with liposomal irinotecan plus 5-FU/leucovorin lived an average of 6.1 months, compared to 4.2 months for those treated with only 5-FU/leucovorin. There was no survival improvement for those who received only liposomal irinotecan compared to those who received ...

TY - JOUR. T1 - A phase II study of high-dose 24 hour continuous infusion 5-FU and leucovorin and low-dose PALA for patients with advanced pancreatic adenocarcinoma. T2 - A Southwest Oncology Group Study. AU - Whitehead, Robert P.. AU - Benedetti, Jacqueline K.. AU - Abbruzzese, James L.. AU - Ardalan, Bach. AU - Goodwin, J. Wendall. AU - Balcerzak, Stanley P.. AU - Samlowski, Wolfram E.. AU - Lenz, Heinz Josef. AU - Macdonald, John S.. N1 - Funding Information: This investigation was supported in part by the following PHS Cooperative Agreement grant numbers awarded by the National Cancer Institute, DHHS: CA38926, CA32102, CA45560, CA04920, CA58861, CA58882, CA46136, CA16385, CA35431, CA13612, CA35261, CA12644, CA12213, CA28862, CA52654, CA14028, CA04919.. PY - 2004/8. Y1 - 2004/8. N2 - Purpose: The purpose of this phase II multi-institutional study was to define the efficacy and toxicity of infusional 5-FU in combination with PALA and leucovorin in patients with advanced pancreatic cancer. ...

The team of doctors randomly assigned 305 patients.. The North Central Cancer Treatment Group Data Safety Monitoring Committee interrupted enrollment when outcomes crossed predetermined stopping boundaries.. The doctors found that results were superior for infused fluorouracil, leucovorin, plus oxaliplatin compared with leucovorin, plus irinotecan for time to progression.. The results were also improved for response rate, and overall survival with infused fluorouracil, leucovorin, plus oxaliplatin.. Toxicity profiles were not different between regimens for nausea, vomiting, diarrhea, febrile neutropenia, dehydration, or 60-day all-cause mortality.. The doctors noted that sensory neuropathy and neutropenia were significantly more common with infused fluorouracil, leucovorin, plus oxaliplatin.. Approximately 75% of patients in both arms received second-line therapy.. The team reported that 58% of leucovorin, plus irinotecan patients received oxaliplatin-based second-line therapy.. About 55% of ...

To estimate progression-free survival (PFS) at 12 months in subjects with metastatic colorectal cancer who receive FOLFIRI [folinic acid (leucovorin or LV),

It is very important that you take leucovorin exactly as directed , especially when it is being taken to counteract the harmful effects of cancer medicine. Do not miss any doses. Also, it is best to take the doses at evenly spaced times day and night. For example, if you are to take 4 doses a day, the doses should be spaced about 6 hours apart. If this interferes with your sleep or other daily activities, or if you need help in planning the best times to take your medicine, check with your health care professional. Do not stop taking leucovorin without checking with your doctor. It is very important that you get exactly the right amount. Dosing- The dose of this medicine will be different for different patients. Follow your doctors orders or the directions on the label. The following information includes only the average doses of this medicine. If your dose is different, do not change it unless your doctor tells you to do so. The amount of medicine that you take depends on the strength of the ...

Phase III study of cyclophosphamide, doxorubicin, and fluorouracil (CAF) plus leucovorin versus CAF for metastatic breast cancer: Cancer and Leukemia Group B 9140 Academic Article ...

Treatment with CS-1008 in combination with FOLFIRI (irinotecan, leucovorin, and 5-fluorouracil [5-FU]) in subjects with metastatic colorectal cancer (CRC) who

The maker of a leucovorin calcium injection has recalled three lots of the product after detecting particulate matter in affected lots.

Fingerprint Dive into the research topics of Concurrent modulation of 5-fluorouracil with methotrexate and L- leucovorin: An effective and moderately toxic regimen for the treatment of advanced colorectal carcinoma a multicenter phase II study of the southern Italy cooperative oncology group. Together they form a unique fingerprint. ...

RATIONALE: Drugs used in chemotherapy, such as fluorouracil, leucovorin, and irinotecan, use different ways to stop tumor cells from dividing so they st

The purpose of this study is to determine the safety and maximum tolerated dose of the combination taxotere, cisplatin, 5-fluorouracil and leucovorin. W

LEUCOVORIN (loo koe VOR in) is used to prevent or treat the harmful effects of some medicines. This medicine is used to treat anemia caused by a low amount of folic acid in the body. It is also used with 5-fluorouracil (5-FU) to treat colon cancer.. ...

LEUCOVORIN (loo koe VOR in) is used to prevent or treat the harmful effects of some medicines. This medicine is used to treat anemia caused by a low amount of folic acid in the body. It is also used with 5-fluorouracil (5-FU) to treat colon cancer.. ...

How Wellcovorin IV (leucovorin injection) chemotherapy works, side effects, interactions and precautions. Get free tools to track your health.

Looking for online definition of leucovorin calcium in the Medical Dictionary? leucovorin calcium explanation free. What is leucovorin calcium? Meaning of leucovorin calcium medical term. What does leucovorin calcium mean?

TY - JOUR. T1 - Oxaliplatin combined with irinotecan and 5-fluorouracil/leucovorin (OCFL) in metastatic colorectal cancer. T2 - A phase I-II study. AU - Seium, Y.. AU - Stupp, R.. AU - Ruhstaller, T.. AU - Gervaz, P.. AU - Mentha, G.. AU - Philippe, M.. AU - Allal, A.. AU - Trembleau, C.. AU - Bauer, J.. AU - Morant, R.. AU - Roth, Arnaud D.. N1 - Copyright: Copyright 2008 Elsevier B.V., All rights reserved.. PY - 2005/5. Y1 - 2005/5. N2 - Background: A phase I-II multicenter trial was conducted to define the maximal tolerated dose and describe the activity of an OCFL combination using oxaliplatin (OHP), irinotecan (CPT-11) and 5-fluorouracil (FU)/leucovorin (LV) in metastatic colorectal cancer (CRC). Patients and methods: CRC patients not pretreated. with palliative chemotherapy, with performance status ≤ 1 and adequate haematological, kidney and liver function, were eligible. Treatment consisted in weekly 24-h infusion 5-FU (2300 mg/m2 )/LV (30mg) and alternating OHP (70-85 mg/m2, days 1 and ...

PURPOSE The primary aim of this study was to compare the relative efficacy of oral uracil and tegafur (UFT) plus leucovorin (LV) with the efficacy of weekly intravenous fluorouracil (FU) plus LV in prolonging disease-free survival (DFS) and overall survival (OS) after primary surgery for colon carcinoma. PATIENTS AND METHODS Between February 1997 and March 1999, 1,608 patients with stage II and III carcinoma of the colon were randomly assigned to receive either oral UFT+LV or intravenous FU+LV. RESULTS Of the total patients, 47% had stage II colon cancer, and 53% had stage III colon cancer. Median follow-up time was 62.3 months. The estimated hazard ratio (HR) for OS of patients who received UFT+LV versus that of patients who received FU+LV was 1.014 (95% CI, 0.825 to 1.246). The estimated HR for DFS was 1.004 (95% CI, 0.847 to 1.190). Cox proportional hazards model analyses with regard to age (| 60 v | or = 60 years), stage, or number of involved nodes (none v one to three v | or = four nodes)

TY - JOUR. T1 - A phase II study of biweekly oxaliplatin plus infusional 5-fluorouracil and folinic acid (FOLFOX-4) as first-line treatment of advanced gastric cancer patients. AU - De Vita, F.. AU - Orditura, M.. AU - Matano, E.. AU - Bianco, R.. AU - Carlomagno, C.. AU - Infusino, S.. AU - Damiano, V.. AU - Simeone, E.. AU - Diadema, M. R.. AU - Lieto, E.. AU - Castellano, P.. AU - Pepe, S.. AU - De Placido, S.. AU - Galizia, G.. AU - Di Martino, N.. AU - Ciardiello, F.. AU - Catalano, G.. AU - Bianco, A. R.. PY - 2005/5/9. Y1 - 2005/5/9. N2 - The aim of the study was to assess the toxicity and the clinical activity of biweekly oxaliplatin in combination with infusional 5-fluorouracil (5-FU) and folinic acid (FA) administered every 2 weeks (FOLFOX-4 regimen) in patients with advanced gastric cancer (AGC). A total of 61 previously untreated AGC patients were treated with oxaliplatin 85 mg m-2 on day 1, FA 200 mg m-2 as a 2 h infusion followed by bolus 5-FU 400 mg m-2 and a 22 h infusion of 5-FU ...

The U.S. Food and Drug Administration (FDA) has approved panitumumab (Vectibix) for use in combination with FOLFOX (fluorouracil, leucovorin, oxaliplatin) as first-line treatment in patients with wild-type KRAS (exon 2) metastatic colorectal cancer.. This approval converts the accelerated monotherapy approval granted in 2006 to a full approval. Panitumumab was previously approved by the FDA as a monotherapy for patients with EGFR-expressing metastatic colorectal cancer after disease progression and prior treatment with fluoropyrimidine-, oxaliplatin-, and irinotecan-containing chemotherapy. The agent is not indicated for the treatment of patients with KRAS-mutant metastatic colorectal cancer or for whom KRAS mutation status is unknown.. The FDA has also approved the therascreen KRAS test as a companion diagnostic to guide use of panitumumab in the treatment of metastatic colorectal cancer.. Phase III Studies. The approval is based on results from the phase III PRIME and -ASPECCT trials. The ...

TY - JOUR. T1 - Phase III noninferiority trial comparing irinotecan with oxaliplatin, fluorouracil, and leucovorin in patients with advanced colorectal carcinoma previously treated with fluorouracil. T2 - N9841. AU - Kim, George P.. AU - Sargent, Daniel J.. AU - Mahoney, Michelle R.. AU - Rowland, Kendrith M.. AU - Philip, Philip A.. AU - Mitchell, Edith. AU - Mathews, Abraham P.. AU - Fitch, Tom R.. AU - Goldberg, Richard M.. AU - Alberts, Steven R.. AU - Pitot, Henry C.. N1 - Copyright: Copyright 2010 Elsevier B.V., All rights reserved.. PY - 2009/6/10. Y1 - 2009/6/10. N2 - Purpose: The primary goal of this multicenter phase III trial was to determine whether overall survival (OS) of fluorouracil (FU) -refractory patients was noninferior when treated with second-line infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4; arm B) versus irinotecan (arm A). Cross-over to the other treatment on disease progression was mandated. Patients and Methods: Patients who experienced treatment ...

From 2010, a new strategy has been introduced in our institute which added 1 more cycle of chemotherapy in the resting period between completion of radiotherapy and operation. The former schedule was defined as conventional group and the schedule with additional cycle of chemotherapy was defined as intensified group. Our policy for locally advanced rectal cancers is to perform neoadjuvant CRT, curative surgery and adjuvant chemotherapy. Neoadjuvant CRT consists of 50 Gy of radiation (25 fraction) and concomitant 5-FU/LV infusion (5-FU 425 mg/m2/day and folic acid 20 mg/m2/day) being delivered in the first and last 5 days of radiation (conventional 2 cycles of chemotherapy). Curative surgery was performed 6-8 weeks after radiation completion. Total mesorectal excision was performed for mid and low rectal cancer and a tumor-specific mesorectal excision with a 5 cm distal margin was performed for upper rectal cancer. Within 6 weeks after rectal surgery, patients took adjuvant 4 cycles of 5-FU/LV ...

In this controlled, open-label, phase 2/3 trial, we randomly assigned 716 patients with histologically-confirmed advanced clinical stage cT2 or higher or nodal positive stage (cN+), or both, resectable tumours, with no evidence of distant metastases, via central interactive web-based-response system, to receive either three pre-operative and three postoperative 3-week cycles of 50 mg/m2 epirubicin and 60 mg/m2 cisplatin on day 1 plus either 200 mg/m2 fluorouracil as continuous intravenous infusion or 1250 mg/m2 capecitabine orally on days 1 to 21 (ECF/ECX; control group) or four preoperative and four postoperative 2-week cycles of 50 mg/m2 docetaxel, 85 mg/m2 oxaliplatin, 200 mg/m2 leucovorin and 2600 mg/m2 fluorouracil as 24-h infusion on day 1 (FLOT; experimental group). The primary outcome of the trial was overall survival (superiority) analysed in the intention-to-treat population. This trial is registered with ClinicalTrials.gov, number NCT01216644.. ...

Background: Phase II and III trials of docetaxel, cisplatin and fluorouracil (DCF) have shown superior efficacy versus cisplatin and fluorouracil alone but with high rates of hematologic toxicity in metastatic gastric cancer cases. To reduce toxicity while maintaining the efficacy of DCF, we investigated low dose docetaxel (D), cispatin (C) - leucovorin and fluorouracil (De Gramont regimen). Patient and methods: Chemotherapy-naive patients with metastatic gastric cancer (MGC) received D 60 mg/m(2) on day 1 and cisplatin 30 mg/m(2) on day 1-2 and the De Gramont regimen (Folinic acid 400 mg/m(2) on day 1 and 5-FU 2400 mg/m(2)/46h continuous infusion) every 3 weeks. The primary endpoint was response rate. Results: One hundred twenty patients with a median age of 52.5 years (range, 32-78) received a median of 6 cycles (range, 2-12 cycles). Of the 120 evaluable patients, 4 showed complete remission and 36 achieved a partial response. The overall response rate was 56.6%. Twenty eight patients (23.3%) ...

Trinotecan combined with infusional 5-fluorouracil/folinic acid or capecitabine plus celecoxib or placebo in the first-line treatment of patients with metastatic colorectal cancer: EORTC study 40015 ...

Metastatic Colorectal Cancer - Pipeline Review, H1 2014SummaryGlobal Markets Directs, Metastatic Colorectal Cancer - Pipeline Review, H1 2014, provides an overview of the Metastatic Colorectal Cancers therapeutic pipeline.This report provides comprehensive information on the therapeutic development for Metastatic Colorectal Cancer, complete with comparative analysis at various stages, therapeutics

The association between oxaliplatin and 5-fluorouracil (5-FU) has been extensively reported to improve prognosis of gastric cancer patients. The present study is aimed at evaluating response rate and the toxicity profile of the association with oxaliplatin, 5-FU/lecovorin and epirubicin in gastric cancer patients with locally advanced or metastatic disease. Thirty-six patients have been enrolled and 35 evaluated. The treatment schedule was oxaliplatin (100 mg m(-2)), 5-FU (400 mg m(-2)), leucovorin (40 mg m(-2)) and epirubicin (60 mg m(-2)) intravenously. administered every 3 weeks for 6 months, for a total of 185 therapy cycles. Response rate and toxicity were assessed according to the international WHO criteria. Every patient received a mean of 5.3 therapy cycles in a day-hospital setting. Sixteen of 35 patients (46%) showed an objective response, two complete response and 14 partial response. Median time to progression was 33 weeks with an overall median survival of 49 weeks. During the ...

Fingerprint Dive into the research topics of Aflibercept Plus FOLFIRI vs. Placebo Plus FOLFIRI in Second-Line Metastatic Colorectal Cancer: a Post Hoc Analysis of Survival from the Phase III VELOUR Study Subsequent to Exclusion of Patients who had Recurrence During or Within 6 Months of Completing Adjuvant Oxaliplatin-Based Therapy. Together they form a unique fingerprint. ...

This article describes the design and early results of an open-label, nonrandomized phase I/II trial of oral UFT plus leucovorin therapy in combination with bolus injections of epirubicin and cyclophosphamide in patients with advanced or metastatic breast cancer. This study was designed as a cohort dose-escalation study with the principal aims being to determine dose-limiting toxicity, overall toxicity, maximum tolerated dose, tumor response, and time to disease progression. 1

Metastatic Colorectal Cancer Pipeline Review, H2 2012 Global Markets Directs, \Metastatic Colorectal Cancer Pipeline Review, H2 2012\, provides an overview of the Metastatic Colorectal Cancer therapeutic pipeline. This report provides information on the therapeutic development for Metastatic Colorectal Cancer, complete with latest updates, and special features on late-stage and discontinued p

TY - JOUR. T1 - Cetuximab for the first-line treatment of metastatic colorectal cancer.. AU - Meads, C.. AU - Round, J.. AU - Tubeuf, S.. AU - Moore, D. AU - Pennant, M.. AU - Bayliss, S.. PY - 2010/5. Y1 - 2010/5. N2 - This paper presents a summary of the evidence review group (ERG) report into the clinical effectiveness and cost-effectiveness of cetuximab for the first-line treatment of metastatic colorectal cancer (mCRC), in accordance with the licensed indication, based upon the manufacturers submission to the National Institute for Health and Clinical Excellence (NICE) as part of the single technology appraisal process. The ERG project ran between 22 January 2008 and 4 November 2008. The clinical evidence came from two unpublished randomised controlled trials (RCTs) of cetuximab plus chemotherapy versus chemotherapy alone in the first-line treatment of mCRC. A third RCT submitted later compared cetuximab with irinotecan in combination with 5-fluorouracil (5-FU) and folinic acid (FA) and ...

A copy of the full document and background is available on the Internet at http://guidance.nice.org.uk/TA439. This guidance represents the view of the Institute which was arrived at after careful consideration of the available evidence. Health professionals are expected to fully take it into account when exercising their clinical judgement. This guidance does not, however, override the individual responsibility of health professionals to make appropriate decisions in the circumstances of the individual patient, in consultation with the patient and/or guardian or carer ...

First-line treatment with cetuximab plus FOLFIRI, as compared with FOLFIRI alone, reduced the risk of progression of metastatic colorectal cancer. The benefit of cetuximab was limited to patients with KRAS wild-type tumors. (ClinicalTrials.gov number, NCT00154102.)

Bevacizumab (B) and cetuximab (C) are both approved for use in the treatment of metastatic colorectal cancer (mCRC) in the second-line. We examined patient reported symptom burden during second-line treatment of mCRC. Adult mCRC patients treated in the second-line setting with a regimen that included B, C, or chemotherapy only (O) and who had completed ≥ 1 Patient Care Monitor (PCM) surveys as part of routine clinical care were drawn from the ACORN Data Warehouse. Primary endpoints were rash, dry skin, itching, nail changes, nausea, vomiting, fatigue, burning in hands/feet, and diarrhea. Linear mixed models examined change in PCM scores across B, C and O (B = reference). 182 patients were enrolled (B: n = 106, C: n = 38, O: n = 38). Patients were 51% female, 67% Caucasian, with mean age of 62.0 (SD = 12.6). Groups did not differ on demographic or clinical characteristics. The most common second-line regimens were FOLFIRI ± B or C (23.1%) and FOLFOX ± B or C (22.5%). Results showed baseline scores to

Irinotecan combined with bolus 5-fluorouracil and folinic acid Nordicschedule as first-line therapy in advanced colorectal cancer. ...

Combination therapy in second-line treatment of metastatic colorectal cancer Data from rectal cancer metastases multicentre, randomised, controlled phase III clinical study NO support the use of Xeloda in combination with oxaliplatin for the second-line treatment of metastastic colorectal cancer.

Chemotherapy combinations commonly used in the treatment of metastatic colorectal cancer include: fluorouracil (5FU) and leucovorin (FU/LV) leucovorin c...

Background: Gastrointestinal cancer is one of the most common cancers worldwide. Researchers think an unmet need exists to understand and improve treatment options. They want to see if a combination of drugs can help people with metastatic colorectal cancer. Objective: To see if using a combination of VB-111 and nivolumab is safe and will cause colorectal tumors to shrink. Eligibility: People ages 18 and older with microsatellite stable colorectal cancer that has spread to the liver Design: Participants must consent to sample collection protocol 11C0112. Participants will be screened with: Blood tests Scans Tumor samples. If these are not available, participants will have a biopsy. Before they start treatment and with every treatment cycle, participants will have: Physical exams Blood tests Heart tests Before they start treatment and every 4 cycles, participants will have CT or MRI scans. For these, they will lie in a machine that takes pictures of the body. For the MRI, a soft padding or coil will be

Clinical trial for Colorectal Cancer , An open-label phase IIIb study of regorafenib in patients with metastatic colorectal cancer (CRC) who have progressed after standard therapy

The next step was: The efficacy 5-FU/LV in combination with irinotecan or oxaliplatin in patients with metastatic CRC has been well documented in various phase II trials. To determine the most effective sequence of therapy, researchers randomized patients receive either a 2-hour infusion of leucovorin (200 mg/m2 or 400 mg/m2) on day 1 and irinotecan (180 mg/m2) followed by bolus 5-FU (400 mg/m2) and a 46-hour infusion of 5-FU (2400-3000 mg/m2) every 2 weeks (FOLFIRI) or the same regimen with oxaliplatin (100 mg/m2) replacing irinotecan on day 1 (FOLFOX6). Patients received the assigned therapeutic regimen until progression or unacceptable toxicity, at which time they crossed over and received the alternate regimen. Patients in the FOLFIRI group were crossed over to receive FOLFOX6 and those in the FOLFOX6 group were crossed over to the FOLFIRI arm. Of 109 patients randomized to FOLFIRI treatment, 81 (74%) were switched to FOLFOX6. Of 111 patients randomized to FOLFOX6, 69 (62%) switched to ...

Background. Metastatic colorectal cancer has a poor prognosis, and the majority of patients are left with palliative measures. The development seen using medical treatments are reviewed.. Material and methods. A systematic approach to the literature-based evidence of effects from palliative chemotherapy and targeted drugs was aimed at.. Results. The continuous improvements during the past 20-25 years have been documented in several large conclusive trials. At the end of the 1980s, the evidence that chemotherapy should be used at all was very limited, whereas presently most patients can be offered three lines of chemotherapy with or without a targeted drug based upon good scientific evidence. Median survival in trials has gradually improved from about 6 months to above 24 months in the most recent trials. Survival in the populations has, however, not improved to the same extent. Several important issues remain to be solved, such as the best sequence of treatments, what regimens to use in various ...

CHICAGO -- Time off from chemotherapy early in oxaliplatin (Eloxatin)-based treatment for metastatic colorectal cancer may reduce toxicity but impair survival, researchers said.

The striking activity of cisplatin in an otherwise fatal disease, testicular cancer, has been established by 30 years of clinical experience. However, acquired and intrinsic resistance limits its application to a relatively narrow range of tumor types. To broaden the anticancer spectrum of this platinum agent, thousands of structural analogues have been tested. Cisplatin analogues with two amine ligands, such as carboplatin and nedaplatin (approved in Japan), are cross-resistant with cisplatin ( 42). Analogues with different ligands display more diverse activity profiles ( 3). Notably, oxaliplatin, with DACH in place of the two amine ligands, in combination with 5-FU/leucovorin, produced response rates twice that of 5-FU/leucovorin regimens alone in the treatment of colorectal cancer ( 43), against which cisplatin is inactive ( 5). Efforts to understand the differences in oxaliplatin versus cisplatin antitumor activity have focused mainly on the cellular processing of cisplatin-DNA and ...